Ascendia once again ranked on Inc. 5000 list of America’s fastest growing private companies



– The CDMO of leading pharmaceutical specialties is on a list of prestigious companies for the second year in a row –

Posted: October 12, 2021 at 10:26 a.m. EDT|Update: 3 hours ago

NORTH BRUNSWICK, NJ, 12 October 2021 / PRNewswire / – Inc. magazine revealed that Ascendia Pharmaceuticals has gained 3,239 positions on its annual Inc. 5000 list, the country’s most prestigious ranking of fastest growing private companies. The list represents a unique look at the most successful companies in the most dynamic segment of the US economy: its small independent businesses.

Ascendia Pharma is ranked in the 2021 Inc 5000 for the second year in a row.

Ascendia Pharma is included in the Inc 5000 ranking for the second year in a row.

Ascendia is one of the world’s leading contract pharmaceutical formulation development and manufacturing (CDMO) organizations. It has achieved 333% growth over the past three years, placing it at 1,422 in total in the Inc 5000 rankings. Ascendia was also the 32sd-company classified in New Jersey and had 130e in the healthcare segment.

“Our rise in the Inc. 5000 rankings demonstrates Ascendia’s commitment to helping customers overcome the challenges associated with the development of parenteral, oral and topical dosage forms. Our development of specialty formulations and our cGMP manufacturing services at a stage early for these projects contribute to Insoluble Soluble ” said Ascendia founder and CEO Jim huang, Ph.D.

“We continue to expand our services, such as biologics and the ability to offer fast, flexible and small-scale services for early clinical studies in humans. For example, Ascendia will offer advanced and commercial cGMP manufacturing in 2022.. For these reasons, we are confident that we will continue to meet our growth expectations, ”concluded Dr Huang.

Not only have the 2021 Inc. 5000 companies been very competitive in their markets, but this year’s list has also proven to be particularly resilient and flexible given the unprecedented challenges of 2020. Among the 5,000, the growth rate three-year median climbed to 543% and median income reached $ 11.1 million. Together, these companies have created more than 610,000 jobs over the past three years.

The full results of Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region and other criteria, are available at https://www.inc.com/inc5000.

“The 2021 Inc. 5000 list appears to be one of the most important business lists ever compiled,” says Scott Omelianuk, editor-in-chief of Inc. “Building one of the fastest growing companies in the United States each year is a remarkable achievement. To build one in the crisis we have been through is simply amazing. hard work, smart hubs, great leadership and help from a lot of people. “

About Inc. Media
The world’s most trusted business media brand, Inc. gives entrepreneurs the knowledge, tools, connections and community to build great businesses. Its award-winning cross-platform content reaches over 50 million people each month through a variety of channels including websites, newsletters, social media, podcasts and print. Its prestigious Inc. 5000 list, produced annually since 1982, analyzes company data to recognize the fastest growing private companies in United States. The global recognition that comes with inclusion in the 5000 gives founders of top companies the opportunity to engage with an exclusive community of their peers and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Vision Conference is part of a highly regarded portfolio of bespoke events produced by Inc. For more information, visit www.inc.com.

About Ascendia Pharmaceuticals
Ascendia Pharmaceuticals is a specialty pharmaceutical CDMO that provides tailor-made sterile and non-sterile enabling formulations development as well as analytical method development and validation and cGMP manufacturing for new chemical entities, complex dosage forms and product development 505 (B) (2), as well as OTCs and nutraceuticals. Ascendia makes the insoluble soluble through a comprehensive suite of pre-formulation, formulation development, cGMP manufacturing and ICH stability services for parent, oral and topical dosage forms, using our nanoemulsion, nanoparticle and platform nanotechnologies amorphous technology. The company has built its success on its customer-centric culture that exudes its BEST philosophy (Bbrilliant technology, Eexcellent service, Ssuperior quality, and Trust).

View original content to download multimedia:

SOURCE Ascendia

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.


Previous Global Chemical Machining Market Growth (Impact of COVID-19), Overview with Detailed Analysis 2021-2027 - Otterbein 360
Next Global Medical Ablation Technology Market Key Factors 2021 - Boston Scientific, Biosense Webster, Olympus, AtriCure - Otterbein 360

No Comment

Leave a reply

Your email address will not be published.

MENU

Back